Skip to main content
. 2023 Apr 24;28(9):e712–e722. doi: 10.1093/oncolo/oyad086

Figure 3.

Figure 3.

Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) in patients with cardiac dose-limiting toxicity (cDLT). Trend in left ventricular ejection fraction and global longitudinal strain (scale reversed for ease of interpretation) from pre-trastuzumab baseline to final follow-up in individuals who developed cDLT (n = 3).